Revenue: As of FY2025, the actual value is USD 0.EPS: As of FY2025, the actual value is USD -1.55.EBIT: As of FY2025, the actual value is USD -24.75 M.<h3>Segment Revenue</h3><ul><li>Net Revenues from Discontinued Operations (FC2 Business): $4.5 million for the year ended September 30, 2025, compared to $16.9 million for the year ended September 30, 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss from Continuing Operations: - $15.7 million for the year ended September 30, 2025, compared to - $35.3 million for the year ended September 30, 2024.</li><li>Net Loss from Discontinued Operations: - $7.0 million for the year ended September 30, 2025, compared to - $2.5 million for the year ended September 30, 2024.</li><li>Total Net Loss: - $22.7 million for the year ended September 30, 2025, compared to - $37.8 million for the year ended September 30, 2024.</li><li>Research and Development Expenses: $15.6 million for the year ended September 30, 2025, compared to $12.8 million for the year ended September 30, 2024.</li><li>General and Administrative Expenses: $19.9 million for the year ended September 30, 2025, compared to $24.6 million for the year ended September 30, 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: - $30.0 million for the year ended September 30, 2025, compared to - $21.7 million for the year ended September 30, 2024.</li><li>Net Cash Provided by Investing Activities: $25.1 million for the year ended September 30, 2025, compared to $0.1 million for the year ended September 30, 2024.</li><li>Net Cash (Used in) Provided by Financing Activities: - $4.2 million for the year ended September 30, 2025, compared to $36.8 million for the year ended September 30, 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Gain on Sale of ENTADFI Assets: $10.8 million for the year ended September 30, 2025, compared to $1.2 million for the year ended September 30, 2024.</li><li>Gain on Extinguishment of Debt: $8.6 million for the year ended September 30, 2025.</li><li>Change in Fair Value of Equity Securities: - $0.3 million for the year ended September 30, 2025, compared to - $0.2 million for the year ended September 30, 2024.</li></ul><h3>Outlook / Guidance</h3><ul><li>The Company plans to prioritize the use of its internal cash and the net proceeds of any future financings for the development of enobosarm, with a primary near-term focus on funding the planned Phase 2b PLATEAU clinical trial.</li><li>The Company is exploring the possibility of the clinical development of sabizabulin for the treatment of inflammation in atherosclerotic cardiovascular disease, subject to the availability of sufficient funding.</li></ul>

Veru | 10-K: FY2025 Revenue: USD 0